Literature DB >> 33379166

Prognostic Value of Baseline Radiomic Features of 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma.

Kun-Han Lue1, Yi-Feng Wu2,3, Hsin-Hon Lin4,5,6, Tsung-Cheng Hsieh7, Shu-Hsin Liu1,8, Sheng-Chieh Chan3,8, Yu-Hung Chen3,8.   

Abstract

This study investigates whether baseline 18F-FDG PET radiomic features can predict survival outcomes in patients with diffuse large B-cell lymphoma (DLBCL). We retrospectively enrolled 83 patients diagnosed with DLBCL who underwent 18F-FDG PET scans before treatment. The patients were divided into the training cohort (n = 58) and the validation cohort (n = 25). Eighty radiomic features were extracted from the PET images for each patient. Least absolute shrinkage and selection operator regression were used to reduce the dimensionality within radiomic features. Cox proportional hazards model was used to determine the prognostic factors for progression-free survival (PFS) and overall survival (OS). A prognostic stratification model was built in the training cohort and validated in the validation cohort using Kaplan-Meier survival analysis. In the training cohort, run length non-uniformity (RLN), extracted from a gray level run length matrix (GLRLM), was independently associated with PFS (hazard ratio (HR) = 15.7, p = 0.007) and OS (HR = 8.64, p = 0.040). The International Prognostic Index was an independent prognostic factor for OS (HR = 2.63, p = 0.049). A prognostic stratification model was devised based on both risk factors, which allowed identification of three risk groups for PFS and OS in the training (p < 0.001 and p < 0.001) and validation (p < 0.001 and p = 0.020) cohorts. Our results indicate that the baseline 18F-FDG PET radiomic feature, RLNGLRLM, is an independent prognostic factor for survival outcomes. Furthermore, we propose a prognostic stratification model that may enable tailored therapeutic strategies for patients with DLBCL.

Entities:  

Keywords:  18F-FDG; PET; diffuse large B-cell lymphoma; prognosis; radiomics

Year:  2020        PMID: 33379166     DOI: 10.3390/diagnostics11010036

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  6 in total

Review 1.  Radiomics in Oncological PET Imaging: A Systematic Review-Part 2, Infradiaphragmatic Cancers, Blood Malignancies, Melanoma and Musculoskeletal Cancers.

Authors:  David Morland; Elizabeth Katherine Anna Triumbari; Luca Boldrini; Roberto Gatta; Daniele Pizzuto; Salvatore Annunziata
Journal:  Diagnostics (Basel)       Date:  2022-05-27

Review 2.  Radiomics in radiation oncology for gynecological malignancies: a review of literature.

Authors:  Morgan Michalet; David Azria; Marion Tardieu; Hichem Tibermacine; Stéphanie Nougaret
Journal:  Br J Radiol       Date:  2021-05-07       Impact factor: 3.629

3.  Diagnostic value of baseline 18FDG PET/CT skeletal textural features in follicular lymphoma.

Authors:  Julie Faudemer; Nicolas Aide; Anne-Claire Gac; Ghandi Damaj; Jean-Pierre Vilque; Charline Lasnon
Journal:  Sci Rep       Date:  2021-12-10       Impact factor: 4.379

4.  Radiomic Features of 18F-FDG PET in Hodgkin Lymphoma Are Predictive of Outcomes.

Authors:  Yeye Zhou; Yuchun Zhu; Zhiqiang Chen; Jihui Li; Shibiao Sang; Shengming Deng
Journal:  Contrast Media Mol Imaging       Date:  2021-11-22       Impact factor: 3.161

5.  Prognostic Value of Radiomic Features of 18F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells.

Authors:  Yeye Zhou; Jihui Li; Xiaoyi Zhang; Tongtong Jia; Bin Zhang; Na Dai; Shibiao Sang; Shengming Deng
Journal:  Front Oncol       Date:  2022-02-07       Impact factor: 6.244

Review 6.  Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma.

Authors:  Xiao-Jie Liang; Xin-Yu Song; Jia-Lin Wu; Dan Liu; Bing-Yu Lin; Hong-Sheng Zhou; Liang Wang
Journal:  Int J Biol Sci       Date:  2022-01-09       Impact factor: 6.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.